Company news
Neurotech International Ltd. (ASX:NTI) news
Neurotech International Ltd. news releases on 6ix. Latest, Sep 20, 2026: NTI Doses First Patient in Phase 3 Beyond Harmony ASD Study
Press releases & updates
NTI Doses First Patient in Phase 3 Beyond Harmony ASD Study
September 20, 2026
Receipt of Binding Commitments for $4.5m Placement
August 3, 2026
Neurotech secures $3.15 million R&D tax incentive loan
July 14, 2026
US FDA clears IND for NTI164
July 13, 2026
NTI secures Notices of Allowance for US patent applications
July 1, 2026
NTI initiates First Clinical Site for Phase 3 ASD Trial
March 16, 2026
Appendix 4D & Half Year Report
February 26, 2026
Positive 90-day GLP toxicology study results in non-rodents
February 22, 2026
Approval received for NTI164 Phase 3 Clinical Study in ASD
February 1, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 29, 2026
Binding Commitments Received for a $4 Million Placement
December 16, 2025
Trading Halt
December 14, 2025
Neurotech receives $4.73m R&D Tax Incentive Refund
November 11, 2025
US FDA Rare Pediatric Disease Designation in Rett syndrome
October 7, 2025
Appendix 4E & Annual Report to shareholders
August 29, 2025
Positive Human PK Study Results for NTI164
June 1, 2025
NTI164 Preclinical Toxicology Studies Update
May 5, 2025
Appendix 4D and Half Year Accounts
February 27, 2025
Positive Opinion on OMPD for NTI164 in Europe
February 27, 2025
NTI Signs Development Agreement for Cannabinoid Therapies
February 12, 2025
Neurotech Receives $2.44 Million R&D Tax Incentive Refund
January 30, 2025
Neurotech Receives US ODD in Rett Syndrome
November 25, 2024
NTI Receives Ethics Approval to Commence Human PK Study
November 24, 2024
Positive Genomic Effects of NTI164 in PANDAS/PANS Patients
November 14, 2024
Neurotech Appoints Dr Anthony Filippis as MD/CEO
November 10, 2024
US FDA Response to Orphan Drug Request in PANDAS/PANS
October 3, 2024
NTI164 Reverses Immune Dysregulation in PANDAS/PANS Children
September 8, 2024
Neurotech Global Partnering and Registration Strategy
August 11, 2024
Further Significant Improvement in Rett Syndrome Patients
July 30, 2024
Phase II/III autism trial shows further benefits
July 17, 2024
Significant improvement in Autism patients at 12 weeks
July 9, 2024
Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment
June 16, 2024
Further clinical benefit at 52 weeks in PANDAS/PANS patients
June 5, 2024
Rett Syndrome Phase I/II trial shows significant benefits
May 5, 2024
Neurotech Completes $10 Million Capital Raise
April 17, 2024
Positive Top-Line Rett Syndrome Clinical Trial Results
April 17, 2024
Phase II/III ASD Trial Successfully Meets Primary Endpoint
April 17, 2024
Last Patient Completes Treatment in NTIASD2 Clinical Trial
April 9, 2024
Rett Syndrome Patients to Receive NTI164 for 52 Weeks
March 12, 2024
PANDAS/PANS Patients Show Continued Clinical Improvement
February 20, 2024
Neurotech Receives Additional HREC Approval in Autism
February 12, 2024
NTI Receives HREC Approval for Cerebral Palsy Trial
January 28, 2024
Phase II/III Autism Clinical Trial Completes Recruitment
December 18, 2023
HREC Approval to Extend Phase II/III ASD Trial to Adults
December 3, 2023
Neurotech Receives $3.17 Million R&D Tax Incentive Refund
November 14, 2023
Phase I/II PANDAS/PANS Clinical Trial Meets Primary Endpoint
October 5, 2023
Completion of Patient Recruitment in NTIRTT1 Clinical Trial
September 26, 2023
Last Patient Completes Treatment in NTIPANS1 Clinical Trial
August 30, 2023
Appendix 4E & Annual Report
August 30, 2023
First Patient Treated in Rett Syndrome Clinical Trial
August 1, 2023